All In Biotech

Drug Trial Radar · NCT05028946

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

A Phase IB Multiple Ascending Dose Study of Safety and Tolerability of Orally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, in Subjects With Moderate to Severely Active Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

May 1, 2022

Primary completion

Jul 7, 2023

Study completion Nov 7, 2023

Sponsor

Lead sponsor
Tiziana Life Sciences LTDIndustry
Sponsor type
Industry
First posted
Aug 31, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to establish the safety and tolerability of multiple ascending doses (MAD) of foralumab enteric coated capsules administered orally, once daily for 5 days per week over 2 weeks in participants with moderate to severely active Crohn's Disease (CD).

Conditions

  • Crohn's Disease

Interventions

  • ForalumabDrug

    Foralumab will be administered per dose and schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Day 1 up to Day 14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.